Does the media refer more to ABEO or ALKS?

In the previous week, Alkermes had 4 more articles in the media than Abeona Therapeutics. MarketBeat recorded 8 mentions for Alkermes and 4 mentions for Abeona Therapeutics. Alkermes' average media sentiment score of 1.07 beat Abeona Therapeutics' score of 0.63 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, MEDP or ALKS?

Medpace has higher revenue and earnings than Alkermes. Medpace is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 5.09 $451.12M $15.91 28.34 Alkermes $1.48B 4.83 $241.66M $0.90 47.51

Is MEDP or ALKS more profitable?

Medpace has a net margin of 17.19% compared to Alkermes' net margin of 9.78%. Medpace's return on equity of 120.89% beat Alkermes' return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.19% 120.89% 24.79% Alkermes 9.78% 9.26% 5.66%

Does the media prefer MEDP or ALKS?

In the previous week, Medpace had 26 more articles in the media than Alkermes. MarketBeat recorded 34 mentions for Medpace and 8 mentions for Alkermes. Alkermes' average media sentiment score of 1.07 beat Medpace's score of 0.27 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 7 Very Positive mention(s) 1 Positive mention(s) 24 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alkermes 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ALKS or OMCL?

Alkermes has higher revenue and earnings than Omnicell. Alkermes is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alkermes $1.48B 4.83 $241.66M $0.90 47.51 Omnicell $1.18B 1.61 $2.05M $0.44 95.20

Is ALKS or OMCL more profitable?

Alkermes has a net margin of 9.78% compared to Omnicell's net margin of 1.67%. Alkermes' return on equity of 9.26% beat Omnicell's return on equity. Company Net Margins Return on Equity Return on Assets Alkermes 9.78% 9.26% 5.66% Omnicell 1.67% 4.00% 2.46%

Does the media prefer ALKS or OMCL?

In the previous week, Alkermes had 5 more articles in the media than Omnicell. MarketBeat recorded 8 mentions for Alkermes and 3 mentions for Omnicell. Alkermes' average media sentiment score of 1.07 beat Omnicell's score of 0.92 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omnicell 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALKS or AMN?

In the previous week, AMN Healthcare Services had 6 more articles in the media than Alkermes. MarketBeat recorded 14 mentions for AMN Healthcare Services and 8 mentions for Alkermes. Alkermes' average media sentiment score of 1.07 beat AMN Healthcare Services' score of 0.17 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AMN Healthcare Services 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ALKS or UTHR?

In the previous week, United Therapeutics had 12 more articles in the media than Alkermes. MarketBeat recorded 20 mentions for United Therapeutics and 8 mentions for Alkermes. Alkermes' average media sentiment score of 1.07 beat United Therapeutics' score of 0.48 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Alkermes (ALKS) Competitors

$42.76 +1.44 (+3.48%)

Closing price 04:00 PM Eastern

Extended Trading

$43.16 +0.40 (+0.94%)

As of 06:28 PM Eastern

Compare

ALKS vs. ABEO, MEDP, OMCL, AMN, and UTHR

Should you buy Alkermes stock or one of its competitors? MarketBeat compares Alkermes with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alkermes include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), and United Therapeutics (UTHR). These companies are all part of the "medical" sector.

How does Alkermes compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Alkermes has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	55.60	$71.18M	$0.97	5.85
Alkermes	$1.48B	4.83	$241.66M	$0.90	47.51

Abeona Therapeutics presently has a consensus price target of $19.00, indicating a potential upside of 234.62%. Alkermes has a consensus price target of $45.40, indicating a potential upside of 6.17%. Given Abeona Therapeutics' higher possible upside, analysts plainly believe Abeona Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alkermes	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.76

Alkermes has a net margin of 9.78% compared to Abeona Therapeutics' net margin of 0.00%. Alkermes' return on equity of 9.26% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Alkermes	9.78%	9.26%	5.66%

In the previous week, Alkermes had 4 more articles in the media than Abeona Therapeutics. MarketBeat recorded 8 mentions for Alkermes and 4 mentions for Abeona Therapeutics. Alkermes' average media sentiment score of 1.07 beat Abeona Therapeutics' score of 0.63 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Abeona Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Summary

Alkermes beats Abeona Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Alkermes compare to Medpace?

Medpace (NASDAQ:MEDP) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

78.0% of Medpace shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 20.5% of Medpace shares are owned by insiders. Comparatively, 4.6% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Medpace currently has a consensus target price of $467.08, indicating a potential upside of 3.61%. Alkermes has a consensus target price of $45.40, indicating a potential upside of 6.17%. Given Alkermes' stronger consensus rating and higher probable upside, analysts clearly believe Alkermes is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Alkermes	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.76

Medpace has higher revenue and earnings than Alkermes. Medpace is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	5.09	$451.12M	$15.91	28.34
Alkermes	$1.48B	4.83	$241.66M	$0.90	47.51

Medpace has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

Medpace has a net margin of 17.19% compared to Alkermes' net margin of 9.78%. Medpace's return on equity of 120.89% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.19%	120.89%	24.79%
Alkermes	9.78%	9.26%	5.66%

In the previous week, Medpace had 26 more articles in the media than Alkermes. MarketBeat recorded 34 mentions for Medpace and 8 mentions for Alkermes. Alkermes' average media sentiment score of 1.07 beat Medpace's score of 0.27 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	7 Very Positive mention(s)	1 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alkermes	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Medpace beats Alkermes on 10 of the 17 factors compared between the two stocks.

How does Alkermes compare to Omnicell?

Alkermes (NASDAQ:ALKS) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Alkermes has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Omnicell has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Alkermes has a net margin of 9.78% compared to Omnicell's net margin of 1.67%. Alkermes' return on equity of 9.26% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	9.78%	9.26%	5.66%
Omnicell	1.67%	4.00%	2.46%

In the previous week, Alkermes had 5 more articles in the media than Omnicell. MarketBeat recorded 8 mentions for Alkermes and 3 mentions for Omnicell. Alkermes' average media sentiment score of 1.07 beat Omnicell's score of 0.92 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.2% of Alkermes shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 4.6% of Alkermes shares are held by insiders. Comparatively, 2.9% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Alkermes has higher revenue and earnings than Omnicell. Alkermes is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.83	$241.66M	$0.90	47.51
Omnicell	$1.18B	1.61	$2.05M	$0.44	95.20

Alkermes presently has a consensus price target of $45.40, suggesting a potential upside of 6.17%. Omnicell has a consensus price target of $59.86, suggesting a potential upside of 42.89%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.76
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Alkermes beats Omnicell on 11 of the 16 factors compared between the two stocks.

How does Alkermes compare to AMN Healthcare Services?

Alkermes (NASDAQ:ALKS) and AMN Healthcare Services (NYSE:AMN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

95.2% of Alkermes shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 4.6% of Alkermes shares are held by company insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Alkermes has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

Alkermes currently has a consensus price target of $45.40, suggesting a potential upside of 6.17%. AMN Healthcare Services has a consensus price target of $25.29, suggesting a potential downside of 16.48%. Given Alkermes' stronger consensus rating and higher probable upside, research analysts plainly believe Alkermes is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.76
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Alkermes has a net margin of 9.78% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	9.78%	9.26%	5.66%
AMN Healthcare Services	-0.95%	18.01%	5.19%

In the previous week, AMN Healthcare Services had 6 more articles in the media than Alkermes. MarketBeat recorded 14 mentions for AMN Healthcare Services and 8 mentions for Alkermes. Alkermes' average media sentiment score of 1.07 beat AMN Healthcare Services' score of 0.17 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AMN Healthcare Services	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alkermes has higher earnings, but lower revenue than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.83	$241.66M	$0.90	47.51
AMN Healthcare Services	$2.73B	0.43	-$95.70M	-$0.87	N/A

Summary

Alkermes beats AMN Healthcare Services on 12 of the 17 factors compared between the two stocks.

How does Alkermes compare to United Therapeutics?

Alkermes (NASDAQ:ALKS) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Alkermes has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

United Therapeutics has a net margin of 40.62% compared to Alkermes' net margin of 9.78%. United Therapeutics' return on equity of 19.24% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	9.78%	9.26%	5.66%
United Therapeutics	40.62%	19.24%	17.25%

In the previous week, United Therapeutics had 12 more articles in the media than Alkermes. MarketBeat recorded 20 mentions for United Therapeutics and 8 mentions for Alkermes. Alkermes' average media sentiment score of 1.07 beat United Therapeutics' score of 0.48 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

United Therapeutics has higher revenue and earnings than Alkermes. United Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.83	$241.66M	$0.90	47.51
United Therapeutics	$3.18B	7.33	$1.33B	$27.09	20.28

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 8.6% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alkermes currently has a consensus price target of $45.40, suggesting a potential upside of 6.17%. United Therapeutics has a consensus price target of $619.42, suggesting a potential upside of 12.73%. Given United Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe United Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.76
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

United Therapeutics beats Alkermes on 12 of the 16 factors compared between the two stocks.

Get Alkermes News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALKS vs. The Competition

Export

Metric	Alkermes	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.89B	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	47.51	17.93	22.30	24.19
Price / Sales	4.83	324.62	581.44	138.36
Price / Cash	24.68	116.27	42.31	57.88
Price / Book	3.88	6.63	9.84	6.72
Net Income	$241.66M	$24.20M	$3.57B	$337.19M
7 Day Performance	12.26%	-3.24%	-1.16%	0.48%
1 Month Performance	28.10%	0.53%	3.85%	5.07%
1 Year Performance	36.74%	47.24%	27.40%	34.25%

Alkermes Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALKS Alkermes	2.6193 of 5 stars	$42.76 +3.5%	$45.40 +6.2%	+32.1%	$6.89B	$1.48B	47.51	2,050	Positive News Insider Trade
ABEO Abeona Therapeutics	3.0963 of 5 stars	$5.63 -2.6%	$19.00 +237.5%	-9.4%	$329.43M	$14.54M	5.80	90	Analyst Upgrade
MEDP Medpace	2.1914 of 5 stars	$451.47 +1.0%	$467.08 +3.5%	+49.6%	$12.77B	$2.68B	28.38	6,200	Trending News Insider Trade
OMCL Omnicell	3.7135 of 5 stars	$43.16 -2.2%	$59.86 +38.7%	+38.8%	$2.01B	$1.18B	98.09	3,580
AMN AMN Healthcare Services	1.6146 of 5 stars	$29.47 +1.7%	$25.29 -14.2%	+48.2%	$1.12B	$2.73B	N/A	2,664	Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALKS) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alkermes (ALKS) Competitors

ALKS vs. ABEO, MEDP, OMCL, AMN, and UTHR

How does Alkermes compare to Abeona Therapeutics?

Summary

How does Alkermes compare to Medpace?

Summary

How does Alkermes compare to Omnicell?

Summary

How does Alkermes compare to AMN Healthcare Services?

Summary

How does Alkermes compare to United Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALKS vs. The Competition

Alkermes Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alkermes (ALKS) Competitors

ALKS vs. ABEO, MEDP, OMCL, AMN, and UTHR

How does Alkermes compare to Abeona Therapeutics?

Which has preferable valuation and earnings, ABEO or ALKS?

Do analysts rate ABEO or ALKS?

Is ABEO or ALKS more profitable?

Does the media refer more to ABEO or ALKS?

Do institutionals and insiders believe in ABEO or ALKS?

Which has more volatility & risk, ABEO or ALKS?

Summary

How does Alkermes compare to Medpace?

Do institutionals & insiders believe in MEDP or ALKS?

Do analysts rate MEDP or ALKS?

Which has stronger earnings & valuation, MEDP or ALKS?

Which has more volatility and risk, MEDP or ALKS?

Is MEDP or ALKS more profitable?

Does the media prefer MEDP or ALKS?

Summary

How does Alkermes compare to Omnicell?

Which has more volatility & risk, ALKS or OMCL?

Is ALKS or OMCL more profitable?

Does the media prefer ALKS or OMCL?

Do institutionals and insiders have more ownership in ALKS or OMCL?

Which has higher earnings & valuation, ALKS or OMCL?

Do analysts rate ALKS or OMCL?

Summary

How does Alkermes compare to AMN Healthcare Services?

Do institutionals & insiders hold more shares of ALKS or AMN?

Which has more risk and volatility, ALKS or AMN?

Do analysts rate ALKS or AMN?

Is ALKS or AMN more profitable?

Does the media prefer ALKS or AMN?

Which has preferable valuation & earnings, ALKS or AMN?

Summary

How does Alkermes compare to United Therapeutics?

Which has more volatility & risk, ALKS or UTHR?

Is ALKS or UTHR more profitable?

Does the media favor ALKS or UTHR?

Which has better valuation & earnings, ALKS or UTHR?

Do insiders & institutionals hold more shares of ALKS or UTHR?

Do analysts prefer ALKS or UTHR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALKS vs. The Competition

Alkermes Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools